# Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

> **NCT00543075** · PHASE1 · COMPLETED · sponsor: **Genta Incorporated** · enrollment: 23 (actual)

## Conditions studied

- Normal Renal Function
- Mildly Impaired Renal Function
- Moderately Impaired Renal Function

## Interventions

- **DRUG:** Genasense (oblimersen, G3139)

## Key facts

- **NCT ID:** NCT00543075
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-11
- **Final completion:** 2009-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543075, "Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT00543075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*